A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

NCT ID: NCT02446418

Last Updated: 2019-01-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 423 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-09
• Study Completion Date: 2017-07-20

Brief Summary

The combination of FF, an ICS and VI, an orally inhaled LABA has been developed as a once-daily combination therapy for the long-term maintenance treatment of asthma in adults and children >=12 years of age. Pivotal phase III studies have demonstrated the safety and efficacy of FF/VI in asthma. However, it is increasingly acknowledged that randomised clinical trials tend to be highly controlled and enrol a more highly selected subject population than is expected to be prescribed the medication post-approval. There is a need for data in a more representative population in close to a 'real life' conditions, where physicians have the ability to choose the best treatment in their view for any individual subject and adapt treatments to subjects' characteristics and response. This multi-center, open-label, randomized, parallel group study will evaluate the efficacy and safety of FF/VI compared with two usual ICS/LABA fixed combination (fluticasone propionate/salmeterol [FP/S] or budesonide/formoterol [BUD/F]) in subjects with persistent asthma, in a "close to real life" settings. FF/VI will be administered once-daily (QD) via ELLIPTA dry powder inhaler (DPI) and FP/S or BUD/F will be administered twice daily (BID) via DISKUS™ and TURBUHALER™ DPI respectively. ELLIPTA is a new powder inhaler designed to be easy to use. The total duration of subject participation will be approximately 6 months (24 weeks). ELLIPTA and DISKUS are registered trademarks of the GSK group of companies. TURBUHALER is a registered trademark of AstraZeneca.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fluticasone Furoate/Vilanterol

Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.

Group Type: EXPERIMENTAL

Fluticasone Furoate

Intervention Type: DRUG

FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI

Vilanterol

Intervention Type: DRUG

Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI

FP/S OR BUD/F

Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.

Group Type: ACTIVE_COMPARATOR

Fluticasone propionate

Intervention Type: DRUG

FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI

Salmeterol

Intervention Type: DRUG

Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI

Budesonide

Intervention Type: DRUG

Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI

Formoterol Fumarate

Intervention Type: DRUG

Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI

Interventions

Fluticasone Furoate

FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI

Intervention Type: DRUG

Vilanterol

Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI

Intervention Type: DRUG

Fluticasone propionate

FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI

Intervention Type: DRUG

Salmeterol

Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI

Intervention Type: DRUG

Budesonide

Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI

Intervention Type: DRUG

Formoterol Fumarate

Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Informed consent: Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
• Gender and Age: Male or female subjects aged >=18 and <=75years of age at Screening visit.

Female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies:

Non-reproductive potential defined as: Pre-menopausal females with one of the following - Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Documented Bilateral Oophorectomy. Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause [refer to laboratory reference ranges for confirmatory levels]); Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

Reproductive potential and agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication and until Week 24.

GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in FRP:

This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle or for subjects who are and will continue to be abstinent from penile-vaginal intercourse on a long term and persistent basis: Contraceptive subdermal implant that meets the Standard Operating Procedure (SOP) effectiveness criteria including a <1percent rate of failure per year, as stated in the product label; Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a <1 percent rate of failure per year, as stated in the product label; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Contraceptive vaginal ring; Percutaneous contraceptive patches; Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject; Male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.

• Type of subject: Subjects with documented physician's diagnosis of asthma >=1 year, unsatisfactorily controlled asthma (ACT <20 at Screening and Randomisation visit) treated by ICS alone and intended to be treated by ICS/LABA maintenance therapy; France Only: A subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a Social Security category.
• Current Asthma Therapy: All subjects must be prescribed maintenance therapy and receiving ICS alone without LABA for at least 4 weeks prior to Randomisation visit; Other background asthma medication such as anti-leukotrienes or theophylline is permitted as an alternative to ICS alone, if initiated at least 4 weeks prior to screening visit.
• Subject questionnaires Subjects must be able to complete the questionnaires themselves.

Exclusion Criteria

• History of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months before Screening and Randomisation visit.
• Subjects having a severe and unstable asthma, with ACT score < 15 at Visit 1 and at Visit 2, and/or a history of repeated severe exacerbations (3/year) and/or a severe exacerbation in the previous 6 weeks before Visit 1 and Visit 2.
• Chronic obstructive pulmonary disease (COPD) Respiratory Disease: A subject must not have current evidence or diagnosis of chronic obstructive pulmonary disease at Screening visit.
• Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at screening [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)].
• Other diseases/abnormalities: Subjects with historical or current evidence of uncontrolled or clinically significant disease at Screening and Randomisation visit. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
• Subjects with a history of adverse reaction including immediate or delayed hypersensitivity to any intranasal, inhaled, or systemic corticosteroid and LABA therapy and to components of the inhalation powder (e.g., lactose, magnesium stearate) at Screening and Randomisation visit. In addition, subjects with a history of severe milk protein allergy that, in the opinion of the Investigator, contraindicates the subject's participation will also be excluded.
• Investigational Medications: A subject must not have used any investigational drug within 30 days prior to Randomisation visit or within five half-lives (t½) of the prior investigational study (whichever is longer of the two), (if unsure discuss with the medical monitor prior to screening).
• Chronic user of systemic corticosteroids: A subject who, in the opinion of the Investigator, is considered to be a chronic user of systemic corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening) at Screening visit.
• Subjects treated by the monoclonal antibody omalizumab or mepolizumab at Visit 1. Treatment with omalizumab or mepolizumab is not allowed during the study.
• Subjects involved in other clinical trials at Screening visit.
• Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study.
• Subjects who plan to move away from the geographical area where the study is being conducted during the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Amiens, , France

GSK Investigational Site

Angers, , France

GSK Investigational Site

Avelin, , France

GSK Investigational Site

Bassussarry, , France

GSK Investigational Site

Beauzelle, , France

GSK Investigational Site

Bersée, , France

GSK Investigational Site

Bécon-les-Granits, , France

GSK Investigational Site

Béziers, , France

GSK Investigational Site

Biarritz, , France

GSK Investigational Site

Bourg-des-Comptes, , France

GSK Investigational Site

Broglie, , France

GSK Investigational Site

Bruay-la-Buissière, , France

GSK Investigational Site

Caen, , France

GSK Investigational Site

Cannes, , France

GSK Investigational Site

Carbon-Blanc, , France

GSK Investigational Site

Châtellerault, , France

GSK Investigational Site

Colombey-les-Belles, , France

GSK Investigational Site

Coulounieix-Chamiers, , France

GSK Investigational Site

Cournonterral, , France

GSK Investigational Site

Dessenheim, , France

GSK Investigational Site

Dijon, , France

GSK Investigational Site

Dinard, , France

GSK Investigational Site

Donges, , France

GSK Investigational Site

Ermont, , France

GSK Investigational Site

Fléville-devant-Nancy, , France

GSK Investigational Site

Gémenos, , France

GSK Investigational Site

Gondreville, , France

GSK Investigational Site

Grenay, , France

GSK Investigational Site

Guesnain, , France

GSK Investigational Site

Hatten, , France

GSK Investigational Site

Hinx, , France

GSK Investigational Site

La Bouëxière, , France

GSK Investigational Site

La Fôret Sur Sèvres, , France

GSK Investigational Site

La Riche, , France

GSK Investigational Site

Lambersart, , France

GSK Investigational Site

Laval, , France

GSK Investigational Site

Le Blanc-Mesnil, , France

GSK Investigational Site

Limoges, , France

GSK Investigational Site

Marseille, , France

GSK Investigational Site

Metz-Tessy, , France

GSK Investigational Site

Montauban, , France

GSK Investigational Site

Montpellier, , France

GSK Investigational Site

Montpellier, , France

GSK Investigational Site

Mûrs-Erigné, , France

GSK Investigational Site

Nancy, , France

GSK Investigational Site

Nantes, , France

GSK Investigational Site

Nantes, , France

GSK Investigational Site

Narbonne, , France

GSK Investigational Site

Nice, , France

GSK Investigational Site

Obernai, , France

GSK Investigational Site

Paris, , France

GSK Investigational Site

Perpignan, , France

GSK Investigational Site

Rosiers-d'Égletons, , France

GSK Investigational Site

Rouen, , France

GSK Investigational Site

Royaumeix, , France

GSK Investigational Site

Saint-Etienne, , France

GSK Investigational Site

Saint-Etienne, , France

GSK Investigational Site

Saint-Ouen-la-Rouërie, , France

GSK Investigational Site

Scorbé-Clairvaux, , France

GSK Investigational Site

Segré, , France

GSK Investigational Site

Soulac-sur-Mer, , France

GSK Investigational Site

Strasbourg, , France

GSK Investigational Site

Thouars, , France

GSK Investigational Site

Toul, , France

GSK Investigational Site

Toulon, , France

GSK Investigational Site

Toulouse, , France

GSK Investigational Site

Toulouse, , France

GSK Investigational Site

Verzy, , France

GSK Investigational Site

Vieux-Condé, , France

GSK Investigational Site

Villejuif, , France

GSK Investigational Site

Wattrelos, , France

GSK Investigational Site

Witry-lès-Reims, , France

GSK Investigational Site

Munich, Bavaria, Germany

GSK Investigational Site

Munich, Bavaria, Germany

GSK Investigational Site

Wallerfing, Bavaria, Germany

GSK Investigational Site

Potsdam, Brandenburg, Germany

GSK Investigational Site

Dortmund, North Rhine-Westphalia, Germany

GSK Investigational Site

Rheine, North Rhine-Westphalia, Germany

GSK Investigational Site

Delitzsch, Saxony, Germany

GSK Investigational Site

Leipzg, Saxony, Germany

GSK Investigational Site

Leipzig, Saxony, Germany

GSK Investigational Site

Leipzig, Saxony, Germany

GSK Investigational Site

Leipzig, Saxony, Germany

GSK Investigational Site

Leipzig, Saxony, Germany

GSK Investigational Site

Teuchern, Saxony-Anhalt, Germany

GSK Investigational Site

Geesthacht, Schleswig-Holstein, Germany

GSK Investigational Site

Schmölln, Thuringia, Germany

GSK Investigational Site

Berlin, , Germany

GSK Investigational Site

Berlin, , Germany

GSK Investigational Site

Berlin, , Germany

GSK Investigational Site

Berlin, , Germany

GSK Investigational Site

Berlin, , Germany

GSK Investigational Site

Magdeburg, , Germany

Countries

France; Germany

References

Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin JM. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting beta2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Respir Med. 2018 Aug;141:111-120. doi: 10.1016/j.rmed.2018.06.009. Epub 2018 Jun 9.

Reference Type: DERIVED

PMID: 30053956 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

116492

Identifier Type: -

Identifier Source: org_study_id